Double‐hit lymphoma: So what?

The revised WHO classification moved all aggressive B‐cell lymphomas with a MYC translocation and a concurrent translocation of BCL2 and/or BCL6 into a single diagnostic category. These are the double‐ and triple‐hit lymphomas. These represent a group with typically a poor outcome to conventional therapy, and as a result, intensification of immunochemotherapy has been explored. The optimal approach is far from clear, and recent insight into the biology suggest that they may represent just a subgroup of molecular high‐grade B‐cell lymphomas that maybe identified by gene expression profiling. There are a number of novel therapeutic approaches under investigation.